TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01347034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (RT)
Description: Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy (RT)
Description: Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells
Description: Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities.
Study: NCT03612687

Intervention type: DEVICE
Intervention: Minimally invasive hemodynamic monitoring
Description: Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management

Intervention type: DEVICE
Intervention: Minimally invasive hemodynamic monitoring
Description: Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management

Intervention type: DEVICE
Intervention: Minimally invasive hemodynamic monitoring
Description: Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management

Intervention type: DEVICE
Intervention: Minimally invasive hemodynamic monitoring
Description: Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management
Study: NCT03563937

Intervention type: DRUG
Intervention: Phenprocoumon
Description: Follow the physician's prescription.

Intervention type: DRUG
Intervention: Apixaban
Description: 2.5 mg or 5 mg, twice daily

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg or 20 mg, once daily

Intervention type: DRUG
Intervention: Edoxaban
Description: 30 mg or 60 mg, once daily
Study: NCT01847885

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Smartpatch Peripheral Nerve Stimulation (PNS) System
Description: The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartpatch Peripheral Nerve Stimulation (PNS) System
Description: The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).
Study: NCT02618447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4Dimensional Phase Contrast Magnetic Resonance Angiography
Description: 4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal vein embolization
Study: NCT03877172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: To provide high-flow nasal cannula in the immediate postoperative period after lung resection surgery as compared to conventional face-mask therapy, in a randomized sequence, for 30 minutes.
Study: NCT00743379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
Study: NCT03368183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care delivery algorithim
Description: SCAMP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care delivery algorithim
Description: SCAMP
Study: NCT00419328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~* starting dose: 0.2 μg/m2~* following doses: 0.4, 0.8 and 1.6 μg/m2.~* number of patients: 4 per dose level~Step 2:~* starting dose: 3.2 μg/m2~* following doses: 6.4 and 12.8 μg/m2~* number of patients: 3 per dose level~Step 3:~* starting dose: 19.2 μg/m2~* following doses: 28.8, 43.2 and 64.8 μg/m2~* number of patients: 3 per dose level~Step 4:~* starting dose: 86.2 μg/m2~* following doses: 114.6 and 152.4 μg/m2~* number of patients: 3 per dose level
Study: NCT03786549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pediatric-adult care transition program
Description: Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~* Educative, family (patient and parent), at home~* Psychological, with the patient individually~* Medico-social orientation, group of patients
Study: NCT03887299

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)
Description: Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Wound Care
Description: Wound care will be administered as standard protocol in our institution
Study: NCT03513003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Pacifier
Description: Children swap from their habitual pacifier to the functional pacifier and stop baby bottle

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stop habit
Description: Children stop the use of their pacifier and/or baby bottle
Study: NCT02450578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 400mg
Description: DSM265 400mg, single oral administration in a fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 400mg
Description: DSM265 400mg, single oral administration in a fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 400mg
Description: DSM265 400mg, single oral administration in a fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to DSM265 400 mg
Description: Placebo to DSM265 400mg, single oral administration in a fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to DSM265 400 mg
Description: Placebo to DSM265 400mg, single oral administration in a fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to DSM265 400 mg
Description: Placebo to DSM265 400mg, single oral administration in a fed state

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoite challenge
Description: IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasmodium falciparum sporozoite challenge
Description: IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoite challenge
Description: IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoite challenge
Description: IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone
Description: 250 mg atovaquone, 100 mg proguanil hydrochloride
Study: NCT01568606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Composition Analysis InBody Scale
Description: Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist.
Study: NCT04016311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Drinking/Eating Intervention
Description: Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
Study: NCT00065728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
Description: One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
Study: NCT02347176

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection with placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab Dose 1
Description: Subcutaneous injection with tralokinumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab Dose 2
Description: Subcutaneous injection with tralokinumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab Dose 3
Description: Subcutaneous injection with tralokinumab
Study: NCT02866825

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IFX-1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03511131

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up
Description: Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up
Description: Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up
Description: Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up
Description: Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up
Description: Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up-Control
Description: HIV knowledge control condition, attention-matched to KIU (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up-Control
Description: HIV knowledge control condition, attention-matched to KIU (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up-Control
Description: HIV knowledge control condition, attention-matched to KIU (Informational)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Young Men's Health Project
Description: Motivational enhancement video interviewing condition (Motivational/behavioral)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Young Men's Health Project
Description: Motivational enhancement video interviewing condition (Motivational/behavioral)
Study: NCT02613598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT04031703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy (injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin chemotherapy (injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin chemotherapy (injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide chemotherapy (injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil chemotherapy (injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel chemotherapy (injection)
Study: NCT02026609

Intervention type: OTHER
Intervention: Oral glutamine challenge
Description: Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine

Intervention type: OTHER
Intervention: Psychometric Tests
Description: PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
Study: NCT03607760

Intervention type: DEVICE
Intervention: ECMO
Description: the patients with severe respiratory failure were supported by ECMO

Intervention type: DEVICE
Intervention: conventional mechanical ventilation
Description: the patients with severe respiratory failure were supported by conventional mechanical ventilation
Study: NCT02369276

Intervention type: OTHER
Intervention: ultrasonography and elastography
Description: Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand

Intervention type: OTHER
Intervention: ultrasonography and elastography
Description: Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand

Intervention type: OTHER
Intervention: ultrasonography and elastography
Description: Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand

Intervention type: OTHER
Intervention: ultrasonography and elastography
Description: Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand

Intervention type: OTHER
Intervention: ultrasonography and elastography
Description: Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
Study: NCT03119519

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Definitive Radiotherapy
Description: three-dimensional conformal therapy or intensity modulated radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Local Definitive Radiotherapy
Description: Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Local Definitive Radiotherapy
Description: Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
Study: NCT04567212

Intervention type: GENETIC
Intervention: genetic evaluation
Description: A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.

Intervention type: GENETIC
Intervention: genetic evaluation
Description: A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.

Intervention type: OTHER
Intervention: MicroRNA evaluation
Description: Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients

Intervention type: OTHER
Intervention: MicroRNA evaluation
Description: Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
Study: NCT02914262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-4924
Description: Comparison of different dosages of AKB-4924

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT03682172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-2 (1pmol/kg/min)
Description: Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-2 (10pmol/kg/min)
Description: Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Four hour intravenous infusion with saline water
Study: NCT01112098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Pamphlet
Description: letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
Study: NCT00784966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.